Arcus Biosciences (RCUS) Short-term Investments (2017 - 2026)

Arcus Biosciences' Short-term Investments history runs 10 years deep, the most recent figure standing at $621.0 million for Q1 2026.

• In Q1 2026, Short-term Investments fell 22.86% year-over-year to $621.0 million; the TTM figure through Mar 2026 stood at $621.0 million (down 22.86% YoY), while the FY2025 annual figure was $759.0 million, down 8.33% from the prior year.
• Short-term Investments was $621.0 million for Q1 2026 at Arcus Biosciences, down from $759.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $900.1 million in Q2 2022 to a low of $593.0 million in Q3 2025.
• Historically, Short-term Investments has averaged $743.6 million across 5 years, with a median of $759.0 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Short-term Investments soared 140.76% in 2022, then sank 33.22% in 2025.
• A 5-year view of Short-term Investments shows it stood at $803.0 million in 2022, then decreased by 21.3% to $632.0 million in 2023, then soared by 31.01% to $828.0 million in 2024, then retreated by 8.33% to $759.0 million in 2025, then declined by 18.18% to $621.0 million in 2026.
• The last three Short-term Investments figures came in at $621.0 million (Q1 2026), $759.0 million (Q4 2025), and $593.0 million (Q3 2025), per Business Quant data.